Comparative Pharmacology
Head-to-head clinical analysis: DEPO PROVERA versus MICRONOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPO PROVERA versus MICRONOR.
DEPO-PROVERA vs MICRONOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progestin that suppresses gonadotropin secretion, inhibiting ovulation and causing endometrial thinning.
Progestin-only contraceptive; suppresses ovulation by inhibiting gonadotropin release, thickens cervical mucus, and alters endometrial lining to prevent implantation.
150 mg intramuscularly every 3 months (13 weeks) for contraception; for endometriosis, 50 mg subcutaneously once weekly or 150 mg intramuscularly every 90 days.
0.35 mg orally once daily, taken at the same time each day.
None Documented
None Documented
Terminal elimination half-life is approximately 12-17 hours after single dose, but after multiple doses or depot administration, the half-life extends to about 40-60 hours due to slow release from injection site.
Terminal elimination half-life is approximately 5-14 hours (mean 7.6-8.7 hours). In clinical context, the short half-life requires daily dosing for contraceptive efficacy.
Primarily metabolized in the liver via hydroxylation and conjugation; metabolites are excreted in urine (60-70%) and feces (20-30%). Less than 1% excreted unchanged in urine.
Approximately 50-80% of a dose is excreted in urine as glucuronide and sulfate conjugates of norethindrone and its metabolites; about 20-40% is excreted in feces via biliary elimination.
Category C
Category C
Progestin-Only Contraceptive
Progestin-Only Contraceptive